CVS raises annual COVID-related revenue forecast to $3 billion
Reuters
Published Aug 03, 2022 06:33AM ET
Updated Aug 03, 2022 03:22PM ET
By Bhanvi Satija and Leroy Leo
(Reuters) - CVS Health Corp (NYSE:CVS) on Wednesday lifted its annual outlook for COVID-19-related revenue as it expects sales of over-the-counter coronavirus tests to more than double this year, sending shares up over 5%.
The largest U.S. pharmacy chain also raised its forecast for annual COVID vaccinations by 2 million to 20 million, reflecting the demand for more boosters.
Pharmacy chain operators such as CVS have benefited from distributing COVID vaccines and tests, but demand for lab tests and vaccinations has slowed in recent months as overall coronavirus cases in the United States remain steady.
CVS administered about 6 million COVID shots nationwide in the second quarter, Chief Executive Officer Karen Lynch said, sharply lower from over 20 million in the last quarter of 2021.
The company forecast annual COVID-related revenue of $3 billion, as it now expects sales to drop by about a third compared with its earlier forecast of a two-thirds slump.
CVS also raised its adjusted profit outlook to $8.40-$8.60 per share from $8.20-$8.40 per share after its second-quarter earnings beat Wall Street estimates.
The outlook, especially for its insurance business, is conservative for the second half the year due to COVID-related uncertainty, Evercore analysts Elizabeth Anderson and Michael Newshel said in a note.
Excluding one-off items, the company reported quarterly earnings per share of $2.40 compared with analysts' average estimate of $2.17, as per Refinitiv IBES data.
(By Leroy Leo and Bhanvi Satija in Bengaluru and Caroline Humer in New York; Editing by Vinay Dwivedi)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.